

**6 November 2020**

## **Results of 2020 Annual General Meeting**

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, PYC Therapeutics Limited (the 'Company') advises that the resolutions contained in the Notice of Meeting dated 5 October 2020 and considered at today's Annual General Meeting of Shareholders were all passed by the required majority following a poll conducted at the meeting. The proxies received in respect of each resolution are set in the attached proxy summary.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited.

**ENDS** For further information, please contact:

**INVESTORS**  
Rohan Hockings  
CEO  
[info@pyctx.com](mailto:info@pyctx.com)

**PYC Therapeutics Limited**  
**Annual General Meeting held on Friday, 6 November 2020**  
**Voting Results**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth)

Resolution Details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result Carried/ Not Carried
		For	Against	Discretionary	Abstain/ Excluded	For	Against	Abstain	
1. Remuneration Report	Ordinary	583,626,405	83,485	1,814,167	1,238,940,226	695,247,603	83,485	1,238,940,226	Carried
2. Election - Dr Bernard Hockings	Ordinary	1,822,676,391	-	1,730,667	57,225	1,934,214,089	-	57,225	Carried
3. Approval Long Term Incentive Plan	Ordinary	578,354,062	1,539,405	1,804,167	1,242,766,649	689,965,260	1,539,405	1,242,766,649	Carried
4. Renewal of Proportional Takeover Provisions	Special	1,822,503,891	-	1,864,167	96,225	1,934,175,089	-	96,225	Carried
5. New Constitution	Special	1,822,512,891	40,000	1,864,167	47,225	1,934,184,089	40,000	47,225	Carried

## About PYC Therapeutics

*PYC Therapeutics Limited (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome ‘the delivery challenge’ and provide access for a wide range of potent and precise drug ‘cargoes’ to the ‘undruggable genome’ – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.*

Tel: +61 8 6151 0994

pyctx.com

**PYC Therapeutics Limited**

ACN 098 391 961